U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. DNA Genotek Inc. - 08/01/2017
  1. Warning Letters

CLOSEOUT LETTER

DNA Genotek Inc.


Recipient:
DNA Genotek Inc.

United States

Issuing Office:

United States


  

Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 10903 New Hampshire Ave.
Silver Spring, MD 20993-0002  

AUG 1, 2017

Brian Smith
Senior Vice President and General Manager
DNA Genotek Inc.
500 Palladium Drive, Ottawa
Ontario K2V 1C2 Canada

Dear Brian Smith:

The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter dated December 20, 2013. Based on our evaluation, it appears that your firm has adequately addressed the violations contained in this Warning Letter.

This letter does not relieve your firm from the responsibility of taking all necessary. steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations. The FDA expects your firm to maintain compliance and this letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Donald J. St. Pierre
Acting Deputy Director for
    Patient Safety and Product Quality
Office of In Vitro Diagnostics
    and Radiological Health
Center for Devices and Radiological Health

Back to Top